Innovaderm is now Indero, a dual-focus CRO dedicated to advancing dermatology and rheumatology therapies through expert, end-to-end clinical research. Explore our history and meet our leadership team.
Reinventing Dermatology & Rheumatology Care
Indero takes a holistic approach to clinical research, merging expertise in dermatology and rheumatology to deliver innovative solutions for immune-mediated inflammatory diseases. Our dedicated team tackles the complexities of trials with a patient-centered focus, turning challenges into opportunities.
Director of Clinical Operations at BioMimetix JV, LLC
âThanks to Inderoâs adaptive approach, we sailed through our trial with ease.â
Our History
Indero is one of three brands (Indero, Innovaderm, and Clinago) working together to advance dermatology and rheumatology research. Each pillar contributes in its own unique way to drive progress in immune-mediated inflammatory diseases.
Innovaderm is our dedicated clinical research site for high-quality, hands-on studies. Equipped with the infrastructure and resources essential for dermatology trials, this unit sets the foundation for precise, impactful research.
As a dual-focus CRO, Indero brings decades of expertise to each clinical trial phase. Specializing in dermatology and rheumatology, our team ensures trials are conducted to the highest standards, meeting the demands of immune-mediated inflammatory disease studies.
Clinago, our proprietary patient recruitment platform, provides reliable, accelerated participant enrollment for dermatology and rheumatology studies. Leveraging an expansive patient network, Clinago shortens recruitment timelines, helping clients achieve their study goals.
2000
Innovaderm Founding
Innovaderm began as a clinical research site specializing in dermatology, quickly earning a reputation for quality research and participant care.
2004
Established Strategic Partnerships
Innovaderm formed strategic alliances with research centers across North America, expanding access to high-quality dermatology sites.
2005
Expanded Management Services and Transition to CRO
Evolved into a Clinical Research Organization (CRO), initiating the management of Investigator-Initiated Studies (IIS), cosmetics, and Phase I topical studies, enhancing service offerings.
2014
Focus on Multicenter Studies
Strengthened CRO activities aimed at multicenter studies, enhancing operational efficiency and research outcomes.
Acquired Excelsus Statistics, enhancing biometrics capabilities across various therapeutic areas.
2024
Expanding & Embracing Rheumatology
We expanded our clinical expertise, now boasting European operational hubs in Poland, Spain, and Germany, with operational capabilities to conduct trials all across Europe. We also launched enhanced ï»żregulatory and clinical development consultation services.Â
Our Values
At Indero, our values fuel our commitment to excellence in clinical research. We collaborate, leveraging decades of expertise to support your goals. We embrace innovation, consistently redefining whatâs possible in dermatology and rheumatology. With a proactive focus on clients, patients, and sites, weâre not just advancing scienceâweâre making a meaningful impact in healthcare. We champion cross-functional teamwork, acting with awareness and responsibility. By fostering a safe and collaborative environment, we empower our team to take decisive action. This dedication to personal accountability ensures we deliver the best solutions swiftly and efficiently.
Smarter Together
Seek Out Innovation
Frontline Focus
Dare to Take Action
Philanthropy
At Indero, we are dedicated to philanthropy to improve patientsâ health and quality of life. In the past 5 years, Indero and parent companies have donated several million dollars to research institutes and universities for the advancement of academic medical research.
Our commitment to innovation and patient care makes Indero a place where meaningful impacts are made every day.
Impactful science requires expertise, passion, and a relentless pursuit of excellence. Together, we tackle the complexities of clinical trials, ensuring every study achieves the best possible outcomes.Â
If youâre ready to contribute to meaningful advancements in clinical research, we want you on our team.
Ready to take the next step in dermatology and rheumatology research? Letâs transform the future of immune-mediated inflammatory disease treatment together.
Dr. Robert Bissonnette is the Executive Chairman and founder of Indero. Dr. Bissonnette has conducted nearly 200 studies ranging from proof-of-concept to phase III. As a Key Opinion Leader, he has extensive knowledge of clinical dermatology, clinical research and the dermatology market. He has published over 270 articles and book chapters and gives lectures on various aspects of dermatology at national and international conferences. After receiving his medical degree from the University of Montreal, he completed his residency training in dermatology followed by his clinical research training at McGill University and the University of British Columbia. Dr. Bissonnette served as an associate professor of dermatology at the University of Montreal until 2004. He is regularly invited to advisory board meetings to share his expert opinion on clinical product development. Dr. Bissonnette is internationally renowned for his clinical expertise in atopic dermatitis and psoriasis.
Jeff Smith
Chief Executive Officer
Jeff Smith, CEO of Indero, brings nearly 30 years of experience in the pharmaceutical and CRO industry, having distinguished himself through exceptional leadership, strategic vision, and innovation. Jeff’s expertise spans global operations, growth management, and fostering a collaborative corporate culture. His strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles. Under Jeffâs leadership, Indero continues to expand its capabilities, advancing medical knowledge and new therapies in dermatology and rheumatology. Jeff prioritizes purpose, people, and profitability to drive high performance and organizational excellence.
Dr. Jasmina Jankicevic, MD, MSc, CCRP
Chief Medical and Scientific Officer
Dr. Jasmina Jankicevic is globally recognized as a thought leader in dermatology & medical aesthetics drug/device development. She has led clinical development in dermatology and medical aesthetics for CROs, pharma/biotech, medical device, and cosmetic companies. She has driven program strategy and implementation of 350+ clinical study protocols in 30+ indications while leading global cross-functional teams towards successful regulatory submissions, product launches, and innovative lifecycle management. As a global expert in dermatology clinical development, Dr. Jankicevic has served as an advisor to multiple companies on their way to global regulatory and commercial success of innovative therapeutic solutions for common and rare skin diseases and aesthetic disorders. Dr. Jankicevic holds Doctor of Medicine degree, Master of Medical Sciences degree, and Board-certification in Dermatology and Venereology from the University of Belgrade, Serbia. She is also a Certified Clinical Research Professional, and a trained journalist. Dr. Jankicevic is a sought-after speaker, and author of numerous articles in peer-reviewed and trade journals.
Jason Shuris
Chief Business Officer
Jason Shuris served as Inderoâs Vice President of Business Development from 2018-2021. Following a short leave, he returned to Indero in August 2022 as Chief Business Officer. Jason oversees the sales and marketing activities at the organization. In addition, he plays a key role in strategy planning and execution. Jason began his career in finance, occupying different roles in the accounting departments of privately held hospitals in Boston. He then worked in the life sciences sector as the controller at several biotechnology companies before entering the CRO industry in 2011. To date, he has held various leadership positions at ophthalmology and dermatology-focused CROs. Jason holds a Master of Science in Accounting from Bentley University (MA).
Anne Marie Gaulin is responsible for the creative vision and strategic plan of action for Inderoâs European Expansion initiative. Based in Europe, she will develop the regionâs clinical trial activities and expertise. Anne Marie joined Indero in 2009 as the director of business development. A strategic thinker, she greatly contributed to the success and growth of the company by managing sales, marketing, recruitment, operations and commercial development. Anne Marieâs sound knowledge of clinical trials in dermatology and 25+ yearsâ experience in the pharmaceutical industry fostered strong relationships with our clients. Prior to joining Indero, she worked in business development at Cirion Biopharma, served as an operations manager at Alcan Packaging, and occupied different roles in sales and marketing at RhĂŽne-Poulenc Rorer (now Sanofi) and Sandoz Consumer Health, a division of Novartis.
Diane Leclerc
VP, CRO Operations
Diane is a seasoned executive leader with over 25 years in clinical and project delivery within CRO, biotechnology, and biopharmaceutical sectors. As head of Project Management and Clinical Operations, she oversees Early Phase and Translational Research, Late-Phase Project Management, Clinical Trial Management, and Clinical Monitoring. Her global team spans the Americas, Europe, and Asia, showcasing her ability to lead diverse teams. Diane excels in managing complex clinical programs, fostering client partnerships, and delivering value-driven outcomes. She has expertise in all phases of clinical drug development and medical devices, with experience in various therapeutic areas. Diane holds a Nursing Sciences degree from Laval University and certifications from SOCRA and PMI. Currently pursuing an Executive MBA, she is dedicated to enhancing her strategic capabilities and driving innovation in clinical research and operations.
Pina D'Angelo
VP, Biometrics
Pina DâAngelo holds a masterâs degree in Mathematics and Statistics from McGill University. She has worked in the pharmaceutical industry for over 25 years, both on the generic as well as on the innovator side. Pina has extensive experience in many therapeutic areas in clinical trials ranging from Phase 1 to 4 studies to PK/PD and bioequivalence studies. She has also served as a lecturer of statistics for at various colleges and universities in Montreal and Toronto.
Guillaume Gigon
VP, Technology and AI
Guillaume Gigon joined Indero in 2018 and is currently the Vice President of Technology and AI. Throughout his career, he has held different positions including managing director at a large CRO. Guillaume has 15+ yearsâ experience in the clinical trial and biomedical industries, including project management and validation. He holds a Master of Science in Biochemistry, a DESS in Information Technology and multiple certifications including Certified CSTB Tester, LSS Green Belt and Portfolio Management.
Yvon Leduc serves as the Vice President of Human Resources at Indero. His responsibilities include developing strategies, establishing programs and setting goals for the department while fostering a diverse workplace that allows employees to flourish. Yvon has 25+ years of leadership experience in human resources management. Prior to joining Indero, he was a Senior Director of Human Resources at a global pharmaceutical company. Yvon holds a bachelorâs degree in Industrial Relations from the University of Montreal. He also holds the designation of Chartered Professional in Human Resources (CPHR) from Quebec.
We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
